Polymorphisms in DNA repair and apoptosis-related genes and clinical outcomes of patients with non-small cell lung cancer treated with first-line paclitaxel-cisplatin chemotherapy.
暂无分享,去创建一个
J. Park | H. Jeon | Shin‐Yup Lee | J. Choi | S. Cha | I. Oh | Y. Choi | K. Shin | S. Yoo | Jaehee Lee | W. Lee | K. S. Kim | Hyo‐Gyoung Kang | Yeh Rim Kang | C. Kim | YOUNG CHUL Kim | Y. Kang
[1] Q. Wei,et al. Effect of Polymorphisms in XPD on Clinical Outcomes of Platinum-Based Chemotherapy for Chinese Non-Small Cell Lung Cancer Patients , 2012, PloS one.
[2] Wei Wu,et al. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis , 2012, BMC Cancer.
[3] J. Yokota,et al. Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Hongbing Shen,et al. Prognostic Significance of Survivin Polymorphisms on Non-small Cell Lung Cancer Survival , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] J. Park,et al. Comprehensive analysis of DNA repair gene polymorphisms and survival in patients with early stage non‐small‐cell lung cancer , 2010, Cancer science.
[6] D. Christiani,et al. Germline genetic variation, cancer outcome, and pharmacogenetics. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Jeon,et al. Polymorphisms in Apoptosis-Related Genes and Survival of Patients with Early-Stage Non-Small-Cell Lung Cancer , 2010, Annals of Surgical Oncology.
[8] Lin-Yu Lu,et al. The role of BRCA1 in DNA damage response , 2010, Protein & Cell.
[9] Peter M. Ellis,et al. First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[10] Dong Sun Kim,et al. Polymorphisms in the CASPASE genes and survival in patients with early-stage non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Yuxin Zheng,et al. Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. , 2009, Cancer letters.
[12] R. Dahiya,et al. The bcl2 -938CC genotype has poor prognosis and lower survival in renal cancer. , 2009, The Journal of urology.
[13] A. Bankfalvi,et al. The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Novello,et al. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] E. Shin,et al. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[17] Johan Vansteenkiste,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Ping Yang,et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.
[19] C. H. Kim,et al. Polymorphisms in the survivin gene and the risk of lung cancer. , 2008, Lung cancer.
[20] M. Spitz,et al. Genetic Variants in Cell Cycle Control Pathway Confer Susceptibility to Lung Cancer , 2007, Clinical Cancer Research.
[21] P. Mullan,et al. BRCA1--a good predictive marker of drug sensitivity in breast cancer treatment? , 2006, Biochimica et biophysica acta.
[22] R. Millikan,et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. , 2006, American journal of human genetics.
[23] N. Crawford,et al. Germ line polymorphism in metastatic progression. , 2006, Cancer research.
[24] H. Dienemann,et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. , 2004, Carcinogenesis.
[25] E. Felip,et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. , 2004, Human molecular genetics.
[26] Yong Xu,et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. , 2004, DNA and cell biology.
[27] A. Loktionov. Common gene polymorphisms, cancer progression and prognosis. , 2004, Cancer letters.
[28] J. Minna,et al. Molecular genetics of lung cancer. , 2003, Seminars in oncology.
[29] M. Spitz,et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. , 2003, Lung cancer.
[30] P. Johnston,et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.
[31] R. Ramlau,et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Christopher I Amos,et al. Genetic susceptibility to lung cancer: the role of DNA damage and repair. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[33] K. Hemminki,et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. , 2002, Carcinogenesis.
[34] J. Park,et al. Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. , 2002, Lung cancer.
[35] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[36] R. Locksley,et al. The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.
[37] A. Jemal,et al. Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.
[38] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[39] K. Jöckel,et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. , 2007, Blood.
[40] C. H. Kim,et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.